PLUS1
3.25
-0.15 (-4.41%)
-0.15 (-4.41%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Bio Path Holdings Inc | BPTH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.15 | -4.41% | 3.25 | 19:47:57 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 3.28 | 3.18 | 3.48 | 3.45 | 3.40 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 3.25 | 3.28 | 0.03 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,188 | 308,487 | $ 3.26 | $ 1,005,012 | 1,834,513 | 2.9203 - 15.7432 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:56:09 | 1 | $ 3.28 | USD |
Bio Path Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 12.00M | 3.69M | 3.66M | $ - | $ - | -3.27 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Bio Path News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/22/2020 | 16:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 10/22/2020 | 07:00 | GlobeNewswire Inc. | Bio-Path Receives Notice of Allowance for Strategic Patent.. |
| 9/10/2020 | 16:17 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/09/2020 | 08:00 | GlobeNewswire Inc. | Bio-Path Holdings to Present at the H.C. Wainwright 22nd.. |
| 8/14/2020 | 07:00 | GlobeNewswire Inc. | Bio-Path Holdings Reports Second Quarter 2020 Financial.. |
| 8/13/2020 | 16:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/13/2020 | 16:12 | Edgar (US Regulatory) | Quarterly Report (10-q) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPTH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.94 | 4.94 | 3.18 | 4.07 | 869,434 | -1.69 | -34.21% |
| 1 Month | 4.19 | 6.09 | 3.18 | 5.16 | 2,691,184 | -0.94 | -22.43% |
| 3 Months | 5.02 | 6.09 | 3.18 | 5.12 | 1,060,503 | -1.77 | -35.26% |
| 6 Months | 5.30 | 6.97 | 3.18 | 5.14 | 529,779 | -2.05 | -38.68% |
| 1 Year | 11.55 | 15.7432 | 2.9203 | 5.46 | 329,708 | -8.30 | -71.86% |
| 3 Years | 80.00 | 84.00 | 1.60 | 18.73 | 612,045 | -76.75 | -95.94% |
| 5 Years | 319.98 | 638.00 | 1.60 | 55.31 | 465,383 | -316.73 | -98.98% |
Bio Path Description
| Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. |
